Anika Therapeutics Files 8-K on Financials
Ticker: ANIK · Form: 8-K · Filed: Mar 13, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Anika Therapeutics dropped an 8-K on March 13th detailing their financial results. Check it out.
AI Summary
Anika Therapeutics, Inc. filed an 8-K on March 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 32 Wiggins Avenue, Bedford, Massachusetts.
Why It Matters
This filing provides an update on Anika Therapeutics' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Registrant
- March 13, 2024 (date) — Date of Report
- 32 Wiggins Avenue Bedford, Massachusetts 01730 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Anika Therapeutics, Inc.'s Results of Operations and Financial Condition, and includes Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on March 13, 2024.
What is the principal business address of Anika Therapeutics, Inc.?
The principal executive offices are located at 32 Wiggins Avenue, Bedford, Massachusetts 01730.
What is the Commission File Number for Anika Therapeutics, Inc.?
The Commission File Number is 001-14027.
What is the IRS Employer Identification Number for Anika Therapeutics, Inc.?
The I.R.S. Employer Identification No. is 04-3145961.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-13 16:10:13
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select Mar
Filing Documents
- f8k_031324.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 168KB
- 0001171843-24-001322.txt ( ) — 393KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_031324_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. On March 13, 2024, Anika Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Anika Therapeutics, Inc. dated March 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anika Therapeutics, Inc. Date: March 13, 2024 By: /s/ CHERYL R. BLANCHARD CHERYL R. BLANCHARD President and Chief Executive Officer